CMV reactivation is associated with a lower incidence of relapse after allo-SCT for CML

Bone Marrow Transplantation

Volumn 48, Issue 10, 2013, Pages 1313-1316

  Ito, S ^a   Pophali, P ^a   Co, Wu ^a   Koklanaris, E K ^a   Superata, J ^a   Fahle, G A ^b   Childs, R ^a   Battiwalla, M ^a   Barrett, A J ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

CML; CMV reactivation; HSCT; relapse

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOMEGALOVIRUS ANTIGEN PP65; FLUDARABINE; FOSCARNET; GANCICLOVIR; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROTEIN TYROSINE KINASE INHIBITOR; VALGANCICLOVIR;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BIOPSY; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; COLITIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; CYTOMEGALOVIRUS RETINITIS; CYTOPENIA; DONOR SELECTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EX VIVO STUDY; FEMALE; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; INCIDENCE; LEUKEMIA RELAPSE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; NONMYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RISK FACTOR; SEROLOGY; SURVIVAL RATE; T CELL DEPLETION; TIME TO TREATMENT; TREATMENT OUTCOME; VIRUS REACTIVATION; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGED; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; RECURRENCE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIRUS ACTIVATION; YOUNG ADULT;

EID: 84885584038     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2013.49     Document Type: Article

References (26)

1. Winston DJ, Gale RP. Prevention and treatment of cytomegalovirus infection and disease after bone marrow transplantation in the 1990s. Bone Marrow Transplant 1991; 8: 7-11.
2. Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996; 88: 4063-4071. (Pubitemid 26383133)
3. Einsele H, Ehninger G, Hebart H, Wittkowski KM, Schuler U, Jahn G et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 1995; 86: 2815-2820.
4. Battiwalla M, Wu Y, Bajwa RP, Radovic M, Almyroudis NG, Segal BH et al. Ganciclovir inhibits lymphocyte proliferation by impairing DNA synthesis. Biol Blood Marrow Transplant 2007; 13: 765-770. (Pubitemid 46902442)
5. Boeckh M, Nichols WG. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 2004; 103: 2003-2008. (Pubitemid 38326213)
6. Boeckh M, Nichols WG, Papanicolaou G, Rubin R, Wingard JR, Zaia J. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant 2003; 9: 543-558. (Pubitemid 38351787)
7. Nichols WG, Corey L, Gooley T, Davis C, Boeckh M. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis 2002; 185: 273-282. (Pubitemid 34107239)
8. Elmaagacli AH, Steckel NK, Koldehoff M, Hegerfeldt Y, Trenschel R, Ditschkowski M et al. Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients. Blood 2011; 118: 1402-1412.
9. Behrendt CE, Rosenthal J, Bolotin E, Nakamura R, Zaia J, Forman SJ. Donor and recipient CMV serostatus and outcome of pediatric allogeneic HSCT for acute leukemia in the era of CMV-preemptive therapy. Biol Blood Marrow Transplant 2009; 15: 54-60.
10. Solomon SR, Nakamura R, Read EJ, Leitman SF, Carter C, Childs R et al. Cyclosporine is required to prevent severe acute GVHD following T-cell-depleted peripheral blood stem cell transplantation. Bone Marrow Transplant 2003; 31: 783-788. (Pubitemid 36656670)
11. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094-1097. (Pubitemid 34289682)
12. Cortez KJ, Fischer SH, Fahle GA, Calhoun LB, Childs RW, Barrett AJ et al. Clinical trial of quantitative real-time polymerase chain reaction for detection of cytomegalovirus in peripheral blood of allogeneic hematopoietic stem-cell transplant recipients. J Infect Dis 2003; 188: 967-972. (Pubitemid 37268245)
13. Khoury HJ, Kukreja M, Goldman JM, Wang T, Halter J, Arora M et al. Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis. Bone Marrow Transplant 2011; 47: 810-816.
14. D'Agostino RB, Lee ML, Belanger AJ, Cupples LA, Anderson K, Kannel WB. Relation of pooled logistic regression to time dependent Cox regression analysis: the Framingham Heart Study. Stat Med 1990; 9: 1501-1515.
15. Savani BN, Montero A, Kurlander R, Childs R, Hensel N, Barrett AJ. Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation. Bone Marrow Transplant 2005; 36: 1009-1015. (Pubitemid 41741565)
16. Nakamura R, Battiwalla M, Solomon S, Follmann D, Chakrabarti S, Cortez K et al. Persisting posttransplantation cytomegalovirus antigenemia correlates with poor lymphocyte proliferation to cytomegalovirus antigen and predicts for increased late relapse and treatment failure. Biol Blood Marrow Transplant 2004; 10: 49-57. (Pubitemid 38145739)
17. Parkman R, Cohen G, Carter SL, Weinberg KI, Masinsin B, Guinan E et al. Successful immune reconstitution decreases leukemic relapse and improves survival in recipients of unrelated cord blood transplantation. Biol Blood Marrow Transplant 2006; 12: 919-927.
18. Hoegh-Petersen M, Sy S, Ugarte-Torres A, Williamson TS, Eliasziw M, Mansoor A et al. High Epstein-Barr virus-specific T-cell counts are associated with near-zero likelihood of acute myeloid leukemia relapse after hematopoietic cell transplantation. Leukemia 2012; 26: 359-362.
19. Thomson KJ, Mackinnon S, Peggs KS. CMV-specific cellular therapy for acute myeloid leukemia? Blood 2012; 119: 1088-1090.
20. Barrett AJ. CMV: when bad viruses turn good. Blood 2011; 118: 1193-1194.
21. Hermouet S, Sutton CA, Rose TM, Greenblatt RJ, Corre I, Garand R et al. Qualitative and quantitative analysis of human herpesviruses in chronic and acute B cell lymphocytic leukemia and in multiple myeloma. Leukemia 2003; 17: 185-195. (Pubitemid 36175905)
22. Fletcher JM, Prentice HG, Grundy JE. Natural killer cell lysis of cytomegalovirus (CMV)-infected cells correlates with virally induced changes in cell surface lymphocyte function-associated antigen-3 (LFA-3) expression and not with the CMVinduced down-regulation of cell surface class I HLA. J Immunol 1998; 161: 2365-2374. (Pubitemid 28397050)
23. Della Chiesa M, Falco M, Podesta M, Locatelli F, Moretta L, Frassoni F et al. Phenotypic and functional heterogeneity of human NK cells developing after umbilical cord blood transplantation: a role for human cytomegalovirus? Blood 2012; 119: 399-410.
24. Foley B, Cooley S, Verneris MR, Pitt M, Curtsinger J, Luo X et al. Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C natural killer cells with potent function. Blood 2011; 119: 2665-2674.
25. Savani BN, Rezvani K, Mielke S, Montero A, Kurlander R, Carter CS et al. Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 2006; 107: 1688-1695. (Pubitemid 43242410)
26. Milano F, Pergam SA, Xie H, Leisenring WM, Gutman JA, Riffkin I et al. Intensive strategy to prevent CMV disease in seropositive umbilical cord blood transplant recipients. Blood 2011; 118: 5689-5696.